<?xml version="1.0" encoding="UTF-8"?>
<p>Dengue viruses (DENV) have become the most prevalent arboviruses in the world [
 <xref rid="pone.0221179.ref001" ref-type="bibr">1</xref>]. DENV pose a significant public health and economic burden worldwide with more than 2.5 billion people living in regions of high-risk of infection, particularly in high population density urban centers in inter-tropical countries [
 <xref rid="pone.0221179.ref002" ref-type="bibr">2</xref>]. Symptoms range from fever, characterized by a flu-like febrile illness with or without warning signs, to severe dengue with plasma leakage, bleeding or organ impairment [
 <xref rid="pone.0221179.ref003" ref-type="bibr">3</xref>]. Despite the availability of a licensed vaccine against DENV in several countries, the poor efficacy of the vaccine has prevented a global vaccination program. Additionally, there are no specific antiviral treatment against DENV infection [
 <xref rid="pone.0221179.ref004" ref-type="bibr">4</xref>].
</p>
